Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin

Leukemia Research

Volumn 34, Issue 7, 2010, Pages

  Asano, Hiroki ^a   Yamamoto, Go ^a   Hosoi, Masataka ^a   Takahashi, Tsuyoshi ^a   Hangaishi, Akira ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN AF9; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BLOOD TOXICITY; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 9; CONTINUOUS INFUSION; CYTOGENETICS; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; HUMANS; IDARUBICIN; IMMUNOTOXINS; LEUKEMIA, MONOCYTIC, ACUTE; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953021568     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.006     Document Type: Letter

References (4)

1. Taksin A.L., Legrand O., Raffoux E., de Revel T., Thomas X., Contentin N., et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007, 21:66-71.
2. Richard A.L., Eric L.S., Edward A.S., et al. Final report of the efficacy and safety of Gemtuzumab Ozogamicin(Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442-1452.
3. Sergio A., Stefan S., Roel W., et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study(AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004, 89:950-955.
4. Claudia S., Richard F.S., Karina E., et al. The prognostic value or MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 2005, 90:1626-1634.